Resolves YES if, by December 31, 2027, a company announces positive topline Phase 3 results for a drug whose molecule was discovered or designed primarily with AI (for example candidates from Insilico Medicine, Isomorphic Labs, Recursion, Exscientia or Generate Biomedicines). The company or a major outlet (Nature, STAT, Reuters, Endpoints) has to describe the drug as AI-discovered or AI-designed. Repurposed existing drugs do not count.
Background: in September 2026 I asked an AI for its ten-year forecast, best case and worst case. Its 2027 best-case list included "AI-designed drugs reach late-stage trials; regulators build a fast lane." I am making a market for each checkable point so the forecast can be scored. The full forecast is free: The Forecast: 2027 to 2036, best case and worst case
